News and Trends 7 Oct 2022 Scientists at IRB Barcelona and PCCB create study model for Ewing sarcoma Ewing sarcoma is the second most frequent bone tumor in children, adolescents, and young adults. There is no specific treatment for this disease and current management is still limited to surgery, radiotherapy, and chemotherapy. The long-term survival of patients with metastatic or relapsed Ewing sarcoma is very low. Ewing sarcoma is caused by a single […] October 7, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Oct 2022 New approaches beckon for small cell lung cancer treatment Small cell lung cancer (SCLC) is a particularly aggressive tumor that has so far been treated with standardized measures. However, a study led by MedUni Vienna in Austria has shown for the first time that different SCLC subtypes have specific molecular characteristics, which is why those affected respond in different ways to cancer treatment. This […] October 6, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2022 FDA fast tracks Immutep non-small cell lung cancer candidate Immutep Limited says the United States Food and Drug Administration (FDA) has granted fast track designation to eftilagimod alpha (efti or IMP321) in combination with pembrolizumab for the treatment of first line non-small cell lung cancer (NSCLC). Efti is the company’s first-in-class soluble LAG-3 clinical stage candidate, which activates antigen presenting cells (APC) to engage […] October 5, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2022 OncoSec slashing staff numbers to prioritize pipeline OncoSec Medical Incorporated is restructuring to prioritize development of its lead clinical candidate TAVO (TAVO-EP). TAVO is a plasmid encoding interleukin 12 (IL-12) delivered by intratumoral electroporation. Oncosec is reducing its staff by approximately 45% and prioritizing clinical pipeline activities to reduce operating expenses. The company and remaining employees will focus clinical activities in melanoma […] October 5, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2022 Discovery of how metastatic cancer cells infiltrate the liver may lead to new drugs Approximately 90% of cancer-related deaths are due to metastasis when cancer spreads and forms new tumors. The liver is considered the most vulnerable organ to metastatic cancer: the five-year survival rate after surgery to remove liver metastases is as low as 30 to 50%, so developing treatments to prevent liver metastasis is urgently needed. A […] October 4, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2022 Oncopeptides starts European commercialization of myeloma drug in Germany Swedish biotech company Oncopeptides AB has initiated the commercial launch of Pepaxti (melphalan flufenamide) in Germany. It marks the first market in Europe where the drug is being launched. On August 18, the European Commission granted Pepaxti, in combination with dexamethasone, Marketing Authorization in the European Union and countries in the European Economic Area, for […] October 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2022 Estrella and TradeUP merge to become publicly traded company Estrella Biopharma, Inc. and TradeUP Acquisition Corp. have entered into a definitive business combination agreement that will result in Estrella becoming a publicly listed company. Upon closing of the transaction, TradeUP will be renamed Estrella Immunopharma, Inc. Estrella Biopharma is a preclinical-stage biopharmaceutical company developing CD19-targeted ARTEMIS T-cell therapies under certain license agreements with the […] October 3, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2022 Oxford BioTherapeutics enters into antibody agreement with Genmab Oxford BioTherapeutics (OBT) says Genmab has licensed a novel antibody related to one of OBT’s IO programs. The target was discovered using Oxford BioTherapeutics’ OGAP drug discovery platform, which incorporates one of the world’s largest proteomic databases, integrating clinical, experimental and expression data. Under the terms of the agreement, Genmab will be responsible for the […] October 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2022 Sierra Space and UC San Diego to develop first stem cell research institute in space Sierra Space and University of California San Diego, one of the world’s top 15 research universities and a leader in microgravity research, have formed a new agreement with the goal of defining the future of human health care research in space. In a new memorandum of understanding between the two organizations, Sierra Space and UC […] October 3, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2022 Kling Biotherapeutics doses first patient in advanced solid tumor trial Kling Biotherapeutics BV has dosed the first patient with KBA1412 in its phase 1b trial to evaluate the safety, tolerability, PK/PD, and potential efficacy of KBA1412 in adult patients with advanced solid tumors not responding to standard of care. KBA1412 is a first in class fully human anti-CD9 antibody based on an antibody produced by […] September 29, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 29 Sep 2022 Removing binding sites for an oncogene can slow cancer cell growth, researchers say Cancer cell growth could be slowed down by removing binding sites for an oncogene, researchers from the University of Helsinki have discovered. They have found a mechanism by which an oncogene commonly activated in cancer patients affects the growth rate of cells. In the future, the findings can help in developing new treatments that could […] September 29, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2022 Positive results from study of drug to treat patients with breast cancer published Results from a phase 1b study of a drug to treat patients with androgen receptor positive (AR+) metastatic breast cancer (mBC) in China were published yesterday (September 28). Kintor Pharmaceutical Limited, a clinical stage biotech company has developed Pruxelutamide, an oral new generation AR antagonist which has shown promising activity in heavily pretreated AR+ mBC […] September 29, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email